The effects of platelet-activating factor (PAF) and a PAF antagonist (CV-3988) on smoke inhalation injury in an ovine model.

The role of platelet-activating factor (PAF) in inhalation injury was studied in sheep, using CV-3988, a PAF antagonist. Following smoke exposure, 15 sheep were divided into three groups of five. Group I animals were untreated; group II animals were treated with CV-3988 before and after exposure; group III animals were treated only after exposure. In group I, platelet and WBC counts were markedly changed within 6 hours (p less than 0.05); in the treated groups, alteration of cell counts was not obvious. Blood malondialdehyde (MDA) levels were increased significantly only in group I. Blood PGE2 and TXB2 levels did not differ among the groups. Mean tissue MDA and mean bronchoalveolar lavage fluid (BALF) MDA concentrations were significantly increased in group I (p less than 0.01); mean BALF TXB2 levels were significantly decreased in group I (p less than 0.01). These data suggest that PAF affects inhalation injury through modulation of lipid oxygenation and that PAF antagonists may offer therapeutic benefit in the management of this injury.

[1]  N. Voelkel,et al.  Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury. , 1990, The American journal of physiology.

[2]  J. Siegel,et al.  Sequential Patterns of Eicosanoid, Platelet, and Neutrophil Interactions in the Evolution of the Fulminant Post‐traumatic Adult Respiratory Distress Syndrome , 1989, Annals of surgery.

[3]  島津 岳士.  A dose-responsive model of smoke inhalation injury : severity-related alteration in cardiopulmonary function , 1989 .

[4]  Y. Huang,et al.  Effect of smoke inhalation injury on thromboxane levels and platelet counts. , 1988, Burns, including thermal injury.

[5]  D. Heimbach,et al.  Cardiopulmonary responses after spontaneous inhalation of Douglas fir smoke in goats. , 1988, The Journal of trauma.

[6]  R. Demling,et al.  Endotoxemia produces an increase in arterial but not venous lipid peroxides in sheep. , 1988, Journal of applied physiology.

[7]  N. Voelkel,et al.  Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. , 1987, The Journal of clinical investigation.

[8]  A. Wardlaw,et al.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. , 1986, The Journal of clinical investigation.

[9]  R. J. Demeter,et al.  THE EFFECTS OF A PLATELET-ACTIVATING FACTOR ANTAGONIST (CV-3988) ON ENDOTOXIC AND HEMORRHAGIC SHOCK IN DOGS , 1986 .

[10]  A. Mikulaschek,et al.  Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat. , 1986, Circulatory shock.

[11]  D. Herndon,et al.  The pulmonary lesion of smoke inhalation in an ovine model. , 1986, Circulatory shock.

[12]  H. Nomura,et al.  CV-3988 - a specific antagonist of platelet activating factor (PAF). , 1983, Life sciences.

[13]  L. Boxer,et al.  Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalanine (FMLP) and platelet-activating factor (PAF). , 1982, Journal of immunology.

[14]  L. McManus,et al.  Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). , 1981, Journal of immunology.

[15]  P. Henson,et al.  Production and release of platelet-activating factor (PAF); dissociation from degranulation and superoxide production in the human neutrophil. , 1980, Journal of immunology.

[16]  H. Edwards,et al.  The effect of lactoperoxidase-catalyzed iodination on the integrity of mitochondrial membranes. , 1975, Archives of biochemistry and biophysics.